Hedge Fund - Broadfin Capital

A new filing with the SEC revealed, Kevin Kotler and his hedge fund Broadfin Capital revealed a trimmed stake in MELA Sciences, Inc (NASDAQ:MELA).

Last night, Broadfin Capital, a healthcare focused hedge fund managed by Kevin Kotler, disclosed in a Securities and Exchange Commission filing that it has initiated a 3.5 million share position in Pernix...

Kevin Kotler’s Broadfin Capital, in its latest filing with the Securities and Exchange Commission, has reported ownership of 9.09 million shares of MELA Sciences Inc (NASDAQ:MELA).

Broadfin Capital, led by Kevin Kotler, in a filing with the Securities and Exchange Commission, reported initiating a position in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO).

A week back, Retrophin conducted an underwritten public offering of 4.71 million shares at a price of $8.50 per share.

Kevin Kotler's Broadfin Capital increased its exposure to Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a filing with the SEC showed.

Kevin Kotler's Broadfin Capital has increased its position in Derma Sciences Inc (NASDAQ:DSCI).

In two newly amended filings with the SEC, Kevin Kotler's Broadfin Capital disclosed moves into Horizon Pharma Inc (NASDAQ:HZNP), and Alliqua Inc (OTCMKTS:ALQAD).

Biodel, Broadfin Capital: In a 13G filing reported a few minutes ago, Kevin Kotler's Broadfin Capital disclosed ownership of a 5.2% stake in Biodel Inc (NASDAQ:BIOD), a company engaged in the development...